Sugi Predict

Sugi Predict / Compounds / SCHEMBL18027

SCHEMBL18027

SCHEMBL18027

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)[C@@H](C(=O)O)C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ GPR119 Q8TDV5 1/20 0.43
▸ SETD7 Q8WTS6 1/20 0.42
▸ NR1H2 P55055 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MCL1 Q07820 1/20 0.41
▸ MMP1 P03956 1/20 0.41
▸ MMP3 P08254 1/20 0.41
▸ MMP7 P09237 1/20 0.41
▸ MMP9 P14780 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22227 1.00 HSD17B10 (0.51) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL2364954 1.00 HSD17B10 (0.51) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL28060557 0.92 HSD17B10 (0.48) HSD17B10SMN1; SMN2GPR119SETD7NR1H2
SCHEMBL29695403 0.92 HSD17B10 (0.50) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL282254 0.92 NR1H2 (0.50) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL20051384 0.91 HSD17B10 (0.43) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL2443144 0.91 HSD17B10 (0.49) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL3551502 0.91 HSD17B10 (0.49) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL27671652 0.89 HSD17B10 (0.42) HSD17B10SMN1; SMN2USP2GPR119SETD7
SCHEMBL4662077 0.87 HSD17B10 (0.45) HSD17B10SMN1; SMN2USP2SETD7NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-04-02 — — US disclosed
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 — — US disclosed
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-02-12 — — US disclosed
US-12472165-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-11-18 — — US disclosed
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN THERAPEUTICS LTD (US) 2025-10-30 — — US disclosed
US-12295942-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-05-13 — — US disclosed
US-20250115634-A1 LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF LNCTAC CO., LTD. (CN) 2025-04-10 — — US disclosed
WO-2025064683-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
WO-2025056017-A1 FUSED BICYCLIC HETEROARYLS AS PARG INHIBITORS AND USES THEREOF ZAI LAB (SHANGHAI) CO., LTD. (CN) 2025-03-20 — — WO disclosed
WO-2025058459-A1 NOVEL IMIDAZOPYRIDINE-BASED COMPOUND AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING, ALLEVIATING, OR TREATING GASTROINTESTINAL INFLAMMATORY DISEASES OR GASTRIC ACID-RELATED DISEASES (주)휴온스 2025-03-20 — — WO disclosed
US-20070213340-A1 Farnesyl protein transferase inhibitors SCHERING CORPORATION 2007-09-13 — — US disclosed
US-20060211706-A1 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases SCHERING CORPORATION 2006-09-21 — — US disclosed
US-20060199820-A1 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma SYMPHONY EVOLUTION, INC. 2006-09-07 — — US disclosed
WO-2006065794-A1 FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 2006-06-22 — — WO disclosed
EP-1140904-B1 FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORP (US) 2005-04-20 — — EP disclosed
US-6800636-B2 FOR THERAPY OF CANCER SCHERING CORPORATION 2004-10-05 — — US disclosed
US-20030040520-A1 Farnesyl protein transferase inhibitors GUZI TIMOTHY (US) 2003-02-27 — — US disclosed
US-6362188-B1 ANTICANCER AGENTS SCHERING CORPORATION 2002-03-26 — — US disclosed
EP-1140904-A1 FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2001-10-10 — — EP disclosed
WO-2000037458-A1 FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2000-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040520-A1 Farnesyl protein transferase inhibitors FNTA, FNTB, CETP HSD17B10 1838/4885SMN1; SMN2 4730/4885USP2 411/4885
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C9, SSB, C1S HSD17B10 3161/4885SMN1; SMN2 21/4885USP2 3870/4885
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE IL6ST, GFRA3, GFRA1 HSD17B10 342/4885SMN1; SMN2 36/4885USP2 913/4885
US-20060199820-A1 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma ADAM10, MMP20, MMP10 HSD17B10 152/4885SMN1; SMN2 905/4885USP2 2244/4885
US-20070213340-A1 Farnesyl protein transferase inhibitors FNTB, FNTA, FDPS HSD17B10 1402/4885SMN1; SMN2 4808/4885USP2 858/4885
US-20060211706-A1 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases FNTB, FNTA, FDPS HSD17B10 332/4885SMN1; SMN2 4637/4885USP2 2448/4885
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE GFRA3, IL6ST, GFRA1 HSD17B10 323/4885SMN1; SMN2 37/4885USP2 906/4885
US-12472165-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 HSD17B10 687/4885SMN1; SMN2 96/4885USP2 128/4885
US-12295942-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 HSD17B10 687/4885SMN1; SMN2 96/4885USP2 128/4885
US-20250115634-A1 LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF SIGLEC7, ASGR1, ADGRF1 HSD17B10 2287/4885SMN1; SMN2 4428/4885USP2 2938/4885
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 HSD17B10 687/4885SMN1; SMN2 96/4885USP2 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.